Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma

Xue, Huiying; Liu, Yong; Liao, Jiazhi; Lin, Jie; B, Li; Yuan, Weigang; Lee, Robert J.; Li, Lei; Xu, Cenke; He, Xingxing

doi:10.18632/oncotarget.13431

Cited by 52 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intratumoral injection of miR-375 nanoparticle formulation markedly reduced tumor growth of HepG2 xenograft masses. These findings were confirmed in a second HCC mouse model obtained by hydrodynamic injection of AKT/Ras oncogenes and tail-vein administration of AuNP-miR-375 showing a consistent increase of apoptotic markers and a reduction of tumor nodules and hepatocyte proliferation [24].…”

Section: Xenograft Micesupporting

confidence: 61%

See 1 more Smart Citation

MicroRNAs in Animal Models of HCC

Fornari

Gramantieri

Callegari

et al. 2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC development and progression and influences drug resistance. Therefore, miRNAs have been assayed as putative biomarkers and therapeutic targets. miRNA-based therapeutic approaches demonstrated safety profiles and antitumor efficacy in HCC animal models; nevertheless, caution should be used when transferring preclinical findings to the clinics, due to possible molecular inconsistency between animal models and the heterogeneous pattern of the human disease. In this context, models with defined genetic and molecular backgrounds might help to identify novel therapeutic options for specific HCC subgroups. In this review, we describe rodent models of HCC, emphasizing their representativeness with the human pathology and their usefulness as preclinical tools for assessing miRNA-based therapeutic strategies.

show abstract

Section: Xenograft Micesupporting

confidence: 61%

“…Bottom panel depicts experimental animal models of HCC and successful miRNA treatments reducing tumor burden. miRNA mimics treatments are in green; anti-miRNA (AM) treatments are in red[3][4][5][6][7][8][9]12,[15][16][17][18][19][20][21][22][23][24][25][26][27].…”

mentioning

confidence: 99%

MicroRNAs in Animal Models of HCC

Fornari

Gramantieri

Callegari

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…MicroRNAs are a class of highly conserved endogenous ncRNAs that are characterized by the single-stranded structure and low molecular weight (19)(20)(21)(22)(23)(24)(25) nucleotides in length). 12,13 Numerous miRNAs have been identified as the important modulator for various cellular events, including cell differentiation, proliferation, apoptosis and oncogenesis, through negatively regulating the expression of target genes at posttranscriptional level.…”

Section: Introductionmentioning

confidence: 99%

Hsa_circ_101280 promotes hepatocellular carcinoma by regulating miR‐375/JAK2

Cao

Wang

et al. 2018

Immunol Cell Biol

View full text Add to dashboard Cite

In this study, we sought to predict the effects of a certain circular RNA (circRNA), hsa_circ_101280 (also known as hsa_circ_0100929 and hsa_circ_SLAIN1), on hepatocellular carcinoma (HCC) cells and to determine the potential mechanism. After screening differentially expressed circRNAs in HCC tissues through Gene Expression Omnibus data analysis, hsa_circ_101280 was found to be highly expressed, and its high expression was verified in HCC cell lines with qRT‐PCR along with the low expression of its downstream miRNA miR‐375. Colony formation and flow cytometry assays showed that both hsa_circ_101280 silencing and miR‐375 overexpression restrained proliferation and promoted apoptosis in HCC cells. JAK2 was identified as a downstream mRNA target of miR‐375 by RNA pull‐down and dual‐luciferase reporter gene assays, its expression in HCC cell lines were positively regulated by hsa_circ_101280 and negatively by miR‐375 expression. Furthermore, the silencing of hsa_circ_101280 significantly inhibited the growth of HCC xenografts in nude mice, with the downregulated expression of JAK2. Overall, both the in vitro and in vivo studies revealed that hsa_circ_101280 largely facilitated the tumorigenesis of HCC, characterized by the promoted proliferation and suppressed apoptosis of HCC cells, by sponging miR‐375 and upregulating JAK2.

show abstract

“…These particles can be used as contrast agents for diagnosis by MRI. Gold NPs main accumulation site is in the liver, and thus, it is a promising biomaterials for the treatment of liver cancer [74,75]. Gold NPs are usually capped with either sodium citrate, polyamidoamine dendrimers (PAMAM), or L-aspartate to stabilize the particles and their cellular uptake is usually mediated by clathrin dependent endocytosis.…”

Section: Metallic Npsmentioning

confidence: 99%

Liver Cancer: Current and Future Trends Using Biomaterials

Chew

Moscato

George

et al. 2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer diagnosed and the second leading cause of death worldwide. Despite advancement in current treatments for HCC, the prognosis for this cancer is still unfavorable. This comprehensive review article focuses on all the current technology that applies biomaterials to treat and study liver cancer, thus showing the versatility of biomaterials to be used as smart tools in this complex pathologic scenario. Specifically, after introducing the liver anatomy and pathology by focusing on the available treatments for HCC, this review summarizes the current biomaterial-based approaches for systemic delivery and implantable tools for locally administrating bioactive factors and provides a comprehensive discussion of the specific therapies and targeting agents to efficiently deliver those factors. This review also highlights the novel application of biomaterials to study HCC, which includes hydrogels and scaffolds to tissue engineer 3D in vitro models representative of the tumor environment. Such models will serve to better understand the tumor biology and investigate new therapies for HCC. Special focus is given to innovative approaches, e.g., combined delivery therapies, and to alternative approaches—e.g., cell capture—as promising future trends in the application of biomaterials to treat HCC.

show abstract

Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma

Cited by 52 publications

References 26 publications

MicroRNAs in Animal Models of HCC

MicroRNAs in Animal Models of HCC

Hsa_circ_101280 promotes hepatocellular carcinoma by regulating miR‐375/JAK2

Liver Cancer: Current and Future Trends Using Biomaterials

Contact Info

Product

Resources

About